RELEASE: Eagle Genomics Announces $20M Financing (1)

- Eagle Genomics Announces First Closing of $20M; funding at scale to accelerate the application of microbiome science for global One Health innovation.

RELEASE: Eagle Genomics Announces $20M Financing (1)

- Eagle Genomics Announces First Closing of $20M; funding at scale to accelerate the application of microbiome science for global One Health innovation.

CAMBRIDGE, England, Oct. 31, 2022 PRNewswire/ -- Eagle Genomics, the pioneer of the TechBio platform that applies network science1 to biology, today announced the first closing of its $20 million funding round . The investment will support the development of the e[datascientist]™ 2 platform and continue to drive expansion into global markets and deepening customer impact.

The round is led by abrdn plc, with continued participation from existing investors Environmental Technologies Fund, and a consortium of investors led by Granpool Innovative Investments. The current funding round will remain open for an additional period to allow for additional participation of up to $10 million.

Eagle Genomics continues to mature and expand as a leading TechBio company, a pioneer in applying network science to biological discovery and innovation, in the food and nutrition, AgBio, beauty and personal care, and biopharma industries . The e[datascientist] platform enables enterprise customers to trace digital journeys in data, driving transformational innovations, exploiting cutting-edge scientific discoveries in silico, and supporting differentiated product claims.

Eagle Genomics' goal is to accelerate the bioeconomy through the digital reinvention of life sciences R&D, and the company is increasingly focused on supporting its customers' aspirations in addressing "One Health" challenges. " for more sustainable and impact-oriented product innovation and outcomes. The One Health concept recognizes that the health of humans, animals, and the environment are intimately interconnected, and that the application of technologies to solve in one area can inspire and enable advances in others. Addressing the One Health opportunity requires a focus on, and a deep understanding of, the microbiome3 and host-microbiome interactions as a common denominator across all of these domains.

Eagle Genomics is the leading business platform using cutting-edge graphics technology and network science to drive the bioeconomy. The business problem the platform solves for its clients is networking their scientific data to support breakthrough innovation, for example, understanding key new bioactive ingredients that could provide health benefits, or targeting a particular health benefit and work backwards through data to identify key ingredients. The technical challenge that Eagle Genomics solves is to bridge the "translation gap" so that scientific insights from a number of disparate sources and studies from different industries can be applied to deliver robust, science-based product claims.

Particular innovation journeys that enable differentiated products and product claims include:

Food and nutrition: Personalized and functional nutrition; for example, energy balance, feed efficiency, growth rate, botanicals, food as medicine, precision fermentation, alternative proteins, and ingredient design and differentiation.

Beauty and personal care: Customized/layered cosmetics; for example, skin, mouth, scalp, pre/pro/postbiotics, ingredient manufacturing, cosmeceuticals, and genital health/personal hygiene products.

AgBio: Biofertilizers, microbiome engineering, bioavailability, crops (yield increase, protection, fertility, productivity, climate change adaptation/mitigation), soil treatment and smart agriculture.

BioPharma: microbiome therapeutics, antimicrobial resistance, personalized/layered medicine, gastrointestinal and infectious disease therapeutics, immuno-oncology/autoimmune diseases, and metabolic health.

Anthony Finbow, CEO, Eagle Genomics, said:

"We are the leading platform company using next-generation graphics technology and network science to drive the bioeconomy. We seek to support our enterprise clients in their efforts to achieve more sustainable and impact-oriented innovation outcomes. The current funding It will allow the bioeconomy to be accelerated through the digital reinvention of science."

Alistair Watson, Head of Strategic Innovation - Private Equity, abrdn, stated:

"We believe Eagle Genomics is poised to support an increasing number of large enterprise customers in digitizing R&D and product innovation activities. This investment will support Eagle Genomics' expansion while driving further market penetration." It is also fundamental to the bioeconomy in general, as the importance of microbiome science increases and its applications become more widespread."

Rob Genieser, Environmental Technologies Fund, commented:

"We are delighted to see Eagle Genomics continue to mature and grow. The timing couldn't be better as the world focuses on disease and accelerating in silico innovation. At a time when there is an urgent need for By changing systems to support and protect the biosphere, Eagle Genomics is helping drive sustainability and impact-focused business results. We wish the team all the best in expanding their reach and deepening their capabilities."


1. Network science is the study of complex networks of physical, biological, and social phenomena, and can also be used to further explain and understand these phenomena.

2. e[datascientist]™ is based on the science of networks and multilayer hypergraphs, applying machine learning and AI to provide a data-driven knowledge journey to solve complex problems at scale. It integrates active learning into every step of the microbiome innovation journey, from "descriptive" to "predictive", while identifying mechanisms of action. It has been gaining traction among large household brands, which are striving to demonstrate the link between their latest products, microbiome health, and One Health issues.

3. The microbiome, the ecosystem of bacteria, fungi and viruses present in virtually all living organisms, is directly related to health and has been shown to be affected by the products we use and consume.

Notes to editors

About Eagle Genomics

Eagle Genomics is innovating at the intersection of biology, data science, and bioinformatics to accelerate the bioeconomy through the digital reinvention of life sciences R&D. The company's award-winning AI-augmented knowledge discovery platform, e[datascientist]™, enables scientists to mine multidimensional data in minutes instead of months, to help companies drive science-led innovation to next generation products. It supports the entire innovation workflow - from hypothesis to product claims - helping to bring novel, safer and more sustainable products to market faster in the food and nutrition, beauty and beauty industries. personal care, biotechnology and biopharmaceuticals.

Eagle Genomics is forging strategic relationships with leading microbiome-focused scientific establishments and has helped shape the UK microbiome strategic roadmap. Eagle Genomics is a Cambridge, UK-based company with a global presence, with locations in London's Knowledge Quarter, Hyderabad, India, and the Genome Center in New York, as well as at Station F in Paris, the Parque Scientist from Potsdam (Germany) and kyiv (Ukraine).

More information at

About abrdn

About ETF Partners

Founded in 2006, ETF Partners supports talented entrepreneurs and management teams with investment capital and experience. Our funds come from institutional investors, global companies and family offices. We create value by investing in technology companies that make a difference. We call it sustainability through innovation.

Media contact

Dr Priya KaliaGlobal CommunicationsEagle Genomics

logo - link

View original content: enlace